Company Profile
Orgenesis Stock Price, News & Catalysts
- Ticker:
- ORGS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.10 USD (+205.81%)
Close
Last updated: August 20, 2026
—
Market cap
Why the stock is moving
Current closing-price context is not available for ORGS.
Company overview
Business overview
Orgenesis is a cell-therapy and advanced-manufacturing company focused on decentralized manufacturing, point-of-care cell processing, and enabling infrastructure for regenerative medicine. Its story blends therapeutic ambition with platform and services capability.
Geographic Base and Sector Classification
Orgenesis is headquartered in the United States and listed on NASDAQ, with a global and platform-oriented biotech profile. It sits between cell therapy, manufacturing services, and biotech infrastructure.
Business Model Characteristics
The business model depends on platform partnerships, manufacturing solutions, and the ability to commercialize decentralized cell-therapy workflows. Investors watch strategic deals, platform adoption, and the company's ability to translate infrastructure into revenue.
Position Within the Biotechnology Landscape
Orgenesis occupies a niche infrastructure position within biotech. It is less of a classic drug stock and more of a platform-enablement story tied to cell therapy manufacturing.
Future catalysts
- Orgenesis’ catalysts are cell-therapy manufacturing, point-of-care platform execution, and any update that clarifies how the company is monetizing its assets. The story is still mostly about platform commercialization.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Orgenesis (ORGS)?
Orgenesis (ORGS) most recently closed at 0.10 USD, a +205.81% move versus the previous session.
What does Orgenesis do?
Orgenesis is a cell-therapy and advanced-manufacturing company focused on decentralized manufacturing, point-of-care cell processing, and enabling infrastructure for regenerative medicine. Its story blends therapeutic ambition with platform and services capability.
On which exchange is ORGS stock listed?
Orgenesis (ORGS) is associated with NASDAQ, United States, Biopharma.
What is Orgenesis?
Orgenesis’ catalysts are cell-therapy manufacturing, point-of-care platform execution, and any update that clarifies how the company is monetizing its assets.
Which conditions is Orgenesis targeting with Orgenesis?
Orgenesis’ catalysts are cell-therapy manufacturing, point-of-care platform execution, and any update that clarifies how the company is monetizing its assets.
How does Orgenesis describe recent progress with Orgenesis?
Orgenesis’ catalysts are cell-therapy manufacturing, point-of-care platform execution, and any update that clarifies how the company is monetizing its assets.
What future catalysts are investors watching for Orgenesis?
Orgenesis’ catalysts are cell-therapy manufacturing, point-of-care platform execution, and any update that clarifies how the company is monetizing its assets. The story is still mostly about platform commercialization.